{"disease":{"id":"hemophilia-a-or-b-with-inhibitors","name":"hemophilia a or b with inhibitors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00851721","title":"Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT02764489","title":"FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT02919800","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"OPKO Health, Inc.","has_results":false},{"nct_id":"NCT02484638","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT02448680","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Laboratoire français de Fractionnement et de Biotechnologies","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}